Texas A&M University System has discovered 3C-like proteinase (3CLpro) (SARS-CoV-2; COVID-19 virus) and cytochrome P450 3A4 (CYP3A4) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.
Animal models recapitulating the immune features of chronic hepatitis B (CHB) are very limited. An Osaka University research team has developed a novel murine model of CHB and tested the efficacy and immunomodulating effects of interferon-α (IFN-α) therapy.
Researchers from Gilead Sciences Inc. presented preclinical data for the hepatitis B virus (HBV) vaccine candidates GS-2829 and GS-6779. Conservation analysis and functional immunogenicity screening were applied to identify optimized anti-hepatitis B surface antigen (HBsAg).
An in-depth investigation of the underlying causes of pulmonary symptoms that in some cases persist for months following recovery from the acute stage of COVID-19 has found a distinctive proinflammatory signature in the plasma and airways of affected patients.
Pfizer Inc. and Biontech SE have initiated a phase I study to evaluate the safety, tolerability and immunogenicity of BNT-162b4, a next-generation COVID-19 vaccine candidate that aims to enhance SARS-CoV-2 T-cell responses and potentially broaden protection against COVID-19.
An in-depth investigation of the underlying causes of pulmonary symptoms that in some cases persist for months following recovery from the acute stage of COVID-19 has found a distinctive proinflammatory signature in the plasma and airways of affected patients. The research could provide an explanation for the ongoing interstitial lung disease and fibrosis seen in patients who were hospitalized with severe COVID-19, and also point to neutrophils as a specific therapeutic target.
Atriva Therapeutics GmbH, a small firm founded in 2015 to develop a host-targeted antiviral approach for treating respiratory viral infections, seems to have found itself in thick of it. As the U.S. CDC and other health agencies warn of an uptick in respiratory viral infections – the so-called “tripledemic” of influenza, respiratory syncytial virus and COVID-19 – the German company is gearing up to launch a basket trial testing lead candidate zapnometinib in all three indications.